Page 82 - Read Online

García-Pardo et al. J Cancer Metastasis Treat 2021;7:62 https://dx.doi.org/10.20517/2394-4722.2021.103 Page 19 of 22

59. Rosenwald A, Alizadeh AA, Widhopf G, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B
cell chronic lymphocytic leukemia. J Exp Med 2001;194:1639-47. DOI PubMed PMC
60. Sinha S, Boysen J, Nelson M, et al. Axl activates fibroblast growth factor receptor pathway to potentiate survival signals in B-cell
chronic lymphocytic leukemia cells. Leukemia 2016;30:1431-6. DOI PubMed PMC
61. Ferrajoli A, Manshouri T, Estrov Z, et al. High levels of vascular endothelial growth factor receptor-2 correlate with shortened
survival in chronic lymphocytic leukemia. Clin Cancer Res 2001;7:795-9. PubMed
62. Bairey O, Boycov O, Kaganovsky E, Zimra Y, Shaklai M, Rabizadeh E. All three receptors for vascular endothelial growth factor
(VEGF) are expressed on B-chronic lymphocytic leukemia (CLL) cells. Leuk Res 2004;28:243-8. DOI PubMed
63. Nowakowski GS, Mukhopadhyay D, Wu X, Kay NE. Neuropilin-1 is expressed by chronic lymphocytic leukemia B cells. Leuk Res
2008;32:1634-6. DOI PubMed PMC
64. Piechnik A, Dmoszynska A, Omiotek M, et al. The VEGF receptor, neuropilin-1, represents a promising novel target for chronic
lymphocytic leukemia patients. Int J Cancer 2013;133:1489-96. DOI PubMed
65. Gutiérrez-González A, Aguilera-Montilla N, Ugarte-Berzal E, et al. α4β1 integrin associates with VEGFR2 in CLL cells and
contributes to VEGF binding and intracellular signaling. Blood Adv 2019;3:2144-8. DOI PubMed PMC
66. Saharinen P, Jeltsch M, Santoyo MM, Leppänen V, Alitalo K. The TIE receptor family. In: Wheeler DL, Yarden Y, editors. Receptor
tyrosine kinases: family and subfamilies. Cham: Springer International Publishing; 2015. p. 743-75. DOI
67. Aguayo A, Manshouri T, O'brien S, et al. Clinical relevance of Flt1 and Tie1 angiogenesis receptors expression in B-cell chronic
lymphocytic leukemia (CLL). Leuk Res 2001;25:279-85. DOI PubMed
68. Palma LM, Flamme H, Gerke I, Kreuzer KA. Angiopoietins modulate survival, migration, and the components of the Ang-Tie2
pathway of chronic lymphocytic leukaemia (CLL) cells in vitro. Cancer Microenviron 2016;9:13-26. DOI PubMed PMC
69. Pötzsch B, Gehrke I, Poll-Wolbeck S, Flamme H, Kreuzer KA. Angiopoietin-2/Tie2 signaling in the microenvironment of chronic
lymphocytic leukemia (CLL). Res Cancer Tumor 2014;3:6-18. DOI
70. Maffei R, Fiorcari S, Martinelli S, et al. Angiopoietin-2 acts as a survival factor for chronic lymphocytic leukemia B cells throughout
Tie-2 receptor engagement. Hematol Oncol 2018;36:372-5. DOI PubMed
71. Bogdanovic E, Nguyen VP, Dumont DJ. Activation of Tie2 by angiopoietin-1 and angiopoietin-2 results in their release and receptor
internalization. J Cell Sci 2006;119:3551-60. DOI PubMed
72. Rutella S, Rumi C, Puggioni P, Barberi, Di Mario A, et al. Expression of thrombospondin receptor (CD36) in B-cell chronic
lymphocytic leukemia as an indicator of tumor cell dissemination. Haematologica 1999;84:419-24. PubMed
73. Mateo V, Lagneaux L, Bron D, et al. CD47 ligation induces caspase-independent cell death in chronic lymphocytic leukemia. Nat
Med 1999;5:1277-84. DOI PubMed
74. Mateo V, Brown EJ, Biron G, et al. Mechanisms of CD47-induced caspase-independent cell death in normal and leukemic cells: link
between phosphatidylserine exposure and cytoskeleton organization. Blood 2002;100:2882-90. DOI PubMed
75. Redondo-Muñoz J, Ugarte-Berzal E, García-Marco JA, et al. Alpha4beta1 integrin and 190-kDa CD44v constitute a cell surface
docking complex for gelatinase B/MMP-9 in chronic leukemic but not in normal B cells. Blood 2008;112:169-78. DOI
76. Amigo-Jiménez I, Bailón E, Ugarte-Berzal E, Aguilera-Montilla N, García-Marco JA, García-Pardo A. Matrix metalloproteinase-9 is
involved in chronic lymphocytic leukemia cell response to fludarabine and arsenic trioxide. PLoS One 2014;9:e99993. DOI PubMed
PMC
77. Bailón E, Ugarte-Berzal E, Amigo-Jiménez I, et al. Overexpression of progelatinase B/proMMP-9 affects migration regulatory
pathways and impairs chronic lymphocytic leukemia cell homing to bone marrow and spleen. J Leukoc Biol 2014;96:185-99. DOI
PubMed
78. Aguilera-Montilla N, Bailón E, Uceda-Castro R, et al. MMP-9 affects gene expression in chronic lymphocytic leukemia revealing
CD99 as an MMP-9 target and a novel partner in malignant cell migration/arrest. Oncogene 2019;38:4605-19. DOI PubMed
79. Aguilera-Montilla N, Bailón E, Ugarte-Berzal E, et al. Matrix metalloproteinase-9 induces a pro-angiogenic profile in chronic
lymphocytic leukemia cells. Biochem Biophys Res Commun 2019;520:198-204. DOI PubMed
80. Cohen JA, Bomben R, Pozzo F, et al. An updated perspective on current prognostic and predictive biomarkers in chronic lymphocytic
leukemia in the context of chemoimmunotherapy and novel targeted therapy. Cancers (Basel) 2020;12:894. DOI PubMed PMC
81. Redondo-Muñoz J, Ugarte-Berzal E, Terol MJ, et al. Matrix metalloproteinase-9 promotes chronic lymphocytic leukemia b cell
survival through its hemopexin domain. Cancer Cell 2010;17:160-72. DOI PubMed
82. Tissino E, Pozzo F, Benedetti D, et al. CD49d promotes disease progression in chronic lymphocytic leukemia: new insights from
CD49d bimodal expression. Blood 2020;135:1244-54. DOI PubMed PMC
83. Maffei R, Martinelli S, Castelli I, et al. Increased angiogenesis induced by chronic lymphocytic leukemia B cells is mediated by
leukemia-derived Ang2 and VEGF. Leuk Res 2010;34:312-21. DOI PubMed
84. Hacken E, Burger JA. Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications
for disease pathogenesis and treatment. Biochim Biophys Acta 2016;1863:401-13. DOI PubMed PMC
85. Schulz A, Toedt G, Zenz T, Stilgenbauer S, Lichter P, Seiffert M. Inflammatory cytokines and signaling pathways are associated with
survival of primary chronic lymphocytic leukemia cells in vitro: a dominant role of CCL2. Haematologica 2011;96:408-16. DOI
PubMed PMC
86. Do HTT, Lee CH, Cho J. Chemokines and their receptors: multifaceted roles in cancer progression and potential value as cancer
prognostic markers. Cancers (Basel) 2020;12:287. DOI PubMed PMC
87. Ugarte-Berzal E, Redondo-Muñoz J, Eroles P, et al. VEGF/VEGFR2 interaction down-regulates matrix metalloproteinase-9 via
STAT1 activation and inhibits B chronic lymphocytic leukemia cell migration. Blood 2010;115:846-9. DOI PubMed